CN101658530B - Medicine combination for treating stomach and duodenum diseases - Google Patents
Medicine combination for treating stomach and duodenum diseases Download PDFInfo
- Publication number
- CN101658530B CN101658530B CN2009103064131A CN200910306413A CN101658530B CN 101658530 B CN101658530 B CN 101658530B CN 2009103064131 A CN2009103064131 A CN 2009103064131A CN 200910306413 A CN200910306413 A CN 200910306413A CN 101658530 B CN101658530 B CN 101658530B
- Authority
- CN
- China
- Prior art keywords
- powder
- medicine
- procaine
- stomach
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a medicine combination for treating stomach and duodenum diseases, which comprises 75 to 85 % of aluminium magnesium carbonate powder and 15 to 25% of procaine powder. The combination is prepared by combining the aluminium magnesium carbonate powder and the procaine powder to form a new medicine which can rapidly inhibit the activities of acid and pepsin and also can quickly release the pain in patients suffering from stomach diseases; and the combination of the two raw materials of the medicine can produce certain synergistic effect and is favorable for playing the curative effect of the medicine.
Description
Technical field
The present invention relates to the pharmaceutical preparations technology field, especially a kind of pharmaceutical composition for the treatment of stomach, dudenal disease.
Background technology
Stomach, dudenal disease commonly encountered diseases kind have diseases such as gastritis, peptic ulcer, duodenitis.Symptoms such as main clinical manifestation is epigastric discomfort, scorching hot or pain, anorexia, feel sick, vomiting, acid regurgitation.Various gastritis, peptic ulcer are a global frequently-occurring disease, commonly encountered diseases, the documents and materials analysis points out that the peptic ulcer total incidence may account for population and 10-12%, sickness rate height not only, and symptom has after chronicity, periodical attack, the treatment characteristics such as easily recurrence, be considered to a kind of intractable, intractable disease more, some patient in addition may concurrently bleed profusely, severe complications such as perforated ulcer and pyloric obstruction.
Though it is more to be used for the treatment of the medicine of gastritis, peptic ulcer at present clinically, however the shortcoming below in clinical treatment, existing:
One, for example anticholinergic agents such as atropine, Anisodamine, the probanthine side effect that often has xerostomia, dim eyesight, heart rate to accelerate of a clinical class Western medicine that is usually used in the gastrointestinal tract relieving spasm to stop pain, especially cause dysuria after taking, even can cause the serious side effects of urine retention, therefore, this type of gastrointestinal antispasmodic medicine often is restricted gerontal patient's use.
Two, at present among clinical treatment disease of stomach numerous, still a kind ofly can reach antacid in the Western medicine, can reach the medicine of rapid pain relieving effect again simultaneously according to lacking, and often only have a kind of therapeutic efficiency wherein.For example antacid such as ranitidine, omeprazole medicine only has the effect of very strong reduction gastric acid, and does not have direct relieving spasm to stop pain effect, need add other relieving spasm to stop pain medicine in addition with pain person.The Chinese traditional compound medicine that has analgesic effect often is slow, and does not have remarkable antacid effect.
Summary of the invention
Main purpose of the present invention is the deficiency at treatment disease of stomach medicine in the above-mentioned prior art, a kind of pharmaceutical composition for the treatment of stomach, dudenal disease is provided, this medicine can antacid, can reach simultaneously rapid pain relieving effect again, and the gerontal patient be used the anxiety of no dysuria in back or urine retention.
In order to realize the foregoing invention purpose, the technical solution used in the present invention is as follows:
A kind of pharmaceutical composition for the treatment of stomach, dudenal disease, form by following mass percent with hydrotalcite powder and two kinds of crude drug of procaine powder:
Hydrotalcite powder 75-85%, procaine powder 15-25%.
Can make acceptable drug dosage form on any one pharmaceutics, be good with peroral dosage form, as capsule, tablet, granule, pill etc.When making concrete pharmaceutical preparation, can add various drug forms right amount of auxiliary materials commonly used according to the needs of different dosage form.
As the hydrotalcite powder of one of crude drug, main component is a Basic Magnesium Aluminum Carbonate, and its molecular formula is Al
2Mg
6(OH)
16CO
34H
2O, molecular weight are 604.3; Hydrotalcite is a kind of antacid, its external antacid result shows that it has antiacid effect rapidly and act on characteristics such as lasting, the 1g hydrotalcite can make the artificial gastric acid pH value of 150ml (about PH1.5) rise to PH 3 in 14 seconds, greatly faster than 134 seconds of aluminium hydroxide; Under the same conditions, be 6 times of sodium bicarbonate its action time; And, there are some researches show that also the adsorbable pepsin of hydrotalcite so can suppress pepsic activity, helps the reparation of ulcer wound surface.
Another kind of crude drug procaine, main component is a procaine hydrochloride, its molecular formula is C
13H
20N
2O
2HCl; Be clinical practice a kind of local anesthetic for a long time, can play sealing process, can block the stimulation of focus, thereby pain is alleviated rapidly the central nervous system to the teleneuron of damage mucomembranous surface.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention combines hydrotalcite and two kinds of crude drug of procaine, forms a kind of new medicine, both can reach rapid antacid and suppress pepsic activity, can remove the symptom of disease of stomach patient pain simultaneously again rapidly; And two kinds of crude drug share, and also can produce certain synergistic function, more help bringing into play curative effect of medication.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Percentage among each embodiment is mass percent.
Embodiment 1
The pharmaceutical composition of present embodiment treatment stomach, dudenal disease is made up of following component:
Hydrotalcite powder 80%, procaine powder 20%.
Make capsule, every contains hydrotalcite powder and the common 0.5g of procaine powder.
Embodiment 2
The pharmaceutical composition of present embodiment treatment stomach, dudenal disease is made up of following component:
Hydrotalcite powder 75%, procaine powder 25%.
Make capsule, every contains hydrotalcite powder and the common 0.5g of procaine powder.
Embodiment 3
The pharmaceutical composition of present embodiment treatment stomach, dudenal disease is made up of following component:
Hydrotalcite powder 85%, procaine powder 15%.
Make tablet, every contains hydrotalcite powder and the common 0.5g of procaine powder.
For confirming the therapeutic effect of pharmaceutical composition of the present invention, estimate whether produce synergistic function after two kinds of crude drug make up simultaneously, the inventor has carried out a series of clinical trial observations and comparative study, and main approaches and result are as follows:
1, physical data:
Accept patient's 269 examples for medical treatment.Wherein male 156 examples, women 113 examples.Men and women's ratio is 1.38: 1.The oldest person 68 years old, reckling 15 years old, average 42.5 years old.
Clinical manifestation: Upper abdominal pain 132 examples (upper abdomen distending pain 65 examples wherein, causalgia 38 examples, dull pain 29 examples, Upper abdominal pain companion acid regurgitation 81 examples, epigastric discomfort 34 examples, the glutted companion's belch of upper abdomen, feel sick, vomiting 22 examples.There are 72 examples to merge melena.The course of disease is the shortest 0.5 year, and is the longest 41 years.
2, make a definite diagnosis method:
The all capable gastroscopy of 269 examples is diagnosed as the ulcer A1 phase.Gastric ulcer 142 examples in 269 examples (wherein merge antral gastritis 55 examples, merge bile reflux 37 examples, duodenal bulbar ulcer 84 examples, complex ulcer 43 examples.Having 188 examples to do pathological examination further makes a definite diagnosis.
3, Therapeutic Method:
The sequencing of making a definite diagnosis by patient is divided into 1 group of the embodiment of the invention, 2 groups, 3 groups each 46 examples, hydrotalcite group 45 examples, ranitidine group 44 examples, procaine group 42 examples.Six groups do not have the statistics difference and exist at aspects such as clinical symptoms, ulcer surface size and age, sexes.The various embodiments of the present invention group is taken each 3 of each embodiment pharmaceutical composition, every day 3 times.It is each 1.5 that the hydrotalcite group is taken the hydrotalcite group at every turn, and every day 3 times, it is each 0.15 that the ranitidine group is taken ranitidine, and every day 2 times, the procaine group is taken procaine group powder 0.1, every day 3 times.Each is organized and was for 6 weeks the course of treatment, finishes back check gastroscopic observation ulcer healing situation the course of treatment.All patients require smoking cessation, wine, and diet easily digests nutritious food.
4, curative effect is judged:
Produce effects: treat 3 days colic symptoms and disappear, other transference cure after 7 days, the back ulcer surface healing of 6 weeks;
Effectively: treat 3 days stomachache degree and alleviate more than 50%, other symptom is clearly better, and 6 week back ulcer surfaces dwindle 〉=and 1/2;
Invalid: treating 3 days stomachache do not have obviously alleviate or change its medicine of clothes or 6 week the back ulcer surfaces dwindle＜1/2 or no change.
Total effective rate: produce effects+effectively.
5, result's (stating table 1 as follows)
Table 1 is respectively organized curative effect relatively
Annotate: various embodiments of the present invention group and hydrotalcite group obvious effective rate compare, X
2Difference=8.03,13.8,4.84, P is all＜0.01; Total effective rate is X relatively
2=0.67,0.67,0.05, P all＞0.05.
Various embodiments of the present invention group and procaine group obvious effective rate compare, X
2Respectively=13.10,19.91,9.06, P all＜0.01, total effective rate is X relatively
2=7.06,7.06,3.75, P＜0.01 or＜0.05.
Can find out that from above curative effect comparison the obvious effective rate of various embodiments of the present invention group all apparently higher than single hydrotalcite and single curative effect with the procaine powder used, has highly significant significant difference (P＜0.01) respectively.Analyze reason polyphyly pharmaceutical composition of the present invention in antacid, can remove patient's stomach pain rapidly, pain is eliminated fast more, then helps patient's ordinary circumstance (comprising diet) and obtains early improvement, and then promoted ulcer healing.Point out in the pharmaceutical composition of the present invention and can produce certain synergistic function between two kinds of crude drug, thereby its curative effect is come soon with hydrotalcite or list with procaine than single, come well, and to suffering from the gerontal patient of prostate hyperplasia, pharmaceutical composition of the present invention does not have the anxiety of the serious side effects that causes urine retention, and is safe and reliable.
Claims (3)
1. pharmaceutical composition for the treatment of stomach, dudenal disease, form by following mass percent with hydrotalcite powder and two kinds of crude drug of procaine powder:
Hydrotalcite powder 75-85%, procaine powder 15-25%.
2. pharmaceutical composition according to claim 1 is characterized in that:
Described pharmaceutical composition is an oral Pharmaceutical dosage forms.
3. pharmaceutical composition according to claim 1 is characterized in that:
Described pharmaceutical composition is capsule, tablet or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103064131A CN101658530B (en) | 2009-08-31 | 2009-08-31 | Medicine combination for treating stomach and duodenum diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103064131A CN101658530B (en) | 2009-08-31 | 2009-08-31 | Medicine combination for treating stomach and duodenum diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101658530A CN101658530A (en) | 2010-03-03 |
| CN101658530B true CN101658530B (en) | 2011-06-15 |
Family
ID=41786931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009103064131A Expired - Fee Related CN101658530B (en) | 2009-08-31 | 2009-08-31 | Medicine combination for treating stomach and duodenum diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101658530B (en) |
-
2009
- 2009-08-31 CN CN2009103064131A patent/CN101658530B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101658530A (en) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016062274A1 (en) | Applications of digestive disease medicament in preparing cancer-inhibiting pharmaceutical composition | |
| RU2672248C1 (en) | Use of benzimidazole derivative for the treatment of nocturnal acid breakthrough | |
| US2868693A (en) | Peptic ulcer-treating compositions containing glutamine | |
| CN102526640B (en) | Pantoprazole sodium medicine compound and preparation technology thereof | |
| CN101461816B (en) | Novel use of corilagin | |
| CN101658530B (en) | Medicine combination for treating stomach and duodenum diseases | |
| CN111388436A (en) | Sodium alginate chewable tablet and preparation method thereof | |
| CN109806397A (en) | SGLT2 inhibitor combines the purposes in the drug of the diseases such as preparation treatment hypertension with ARB | |
| KR101488921B1 (en) | Mint liquid for improving digestive functions and manufacturing method thereof | |
| CN107001262A (en) | The hemifumarate and its crystal formation of the proton pump inhibitor containing pyrrole ring, intermediate and medical usage | |
| CN101590031A (en) | Sulfonated dehydro rosin acid disodium, its compositions and application thereof | |
| Pasternak et al. | Spinal cord disorders | |
| CN102210681B (en) | Application of ectoine and derivatives thereof in preparing medicament for treating digestive tract diseases | |
| CN1744896B (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| KR20200100552A (en) | Pharmaceutical Composition comprising benzimidazole derivative compound | |
| WO2006115238A1 (en) | Gastrointestinal motor activation regulator | |
| CN103735693B (en) | One treats the dyspeptic Chinese medicine preparation of caused by hepatic stagnation qi stagnation | |
| CN105232991B (en) | A kind of pharmaceutical composition for treating mucosal lesion | |
| Gaisinskaya et al. | S2225 Necessity of Swallow Evaluations in the Elderly Prior to Capsule Endoscopy | |
| KR102289089B1 (en) | Composition for the treatment or prevention of laryngopharyngeal reflux disease | |
| CN109453331B (en) | Traditional Chinese medicine composition for treating gastric ulcer | |
| CN105640995A (en) | Pharmaceutical composition and applications thereof | |
| CN101480383A (en) | Application of disodium sulfodehydroabietate for treating gastroxia type peptic ulcer and gastrointestinal tract inflammation | |
| CN100361671C (en) | Medicine for treating peptic ulcer | |
| CN108837069A (en) | It is a kind of for treating the Chinese medicine and preparation method of gastric ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110615 Termination date: 20130831 |